Parents 'frustrated' at collapse of school cash app
Parents trying to retrieve money from a pre-payment system for school meals are "disappointed and frustrated" at being charged a £10 administration fee to reclaim funds, a school leader has said.The sQuid app allowed parents to put money on a card so pupils could pay for meals and other items but it ceased UK operations on 14 March.The firm said it announced the move on 3 February, citing "increasingly adverse trading conditions during and post-Covid".Nathan Jeremiah, from Archway Learning Trust, which runs schools across the East Midlands and used the system, said there was about £43,000 owed to about 1,300 parents in the system when the company ceased operation.
"For our parents that is a lot of money," said Mr Jeremiah, chief operating officer at the Nottinghamshire-based trust."We serve [some] incredibly disadvantaged communities where they're putting that money on the account to feed their children, with the intent that that would provide their child with a meal at school."To not have that available for some of the schools and communities we serve, that is a significant sum of money."
Company 'difficult'
Mr Jeremiah said he has been dealing with parents trying to get their money refunded, with the administration fee causing particular anger, and criticised the company for their response."There [have] been complaints, and a lot of noise from parents that are disappointed and frustrated that a company has said in good faith they wouldn't charge [an admin fee] up until that point, and then decided at the last minute that they would," he said."They [sQuid] have been incredibly difficult to deal with, to actually get clarity to provide to parents - they said the normal ways, so [the] app and a website, etc, to be able to get money out of the system and top up, would continue to work, and then they shut the app down almost immediately."It appears to me that every obstacle they could put in [parents'] way, they have."In a statement sQuid said it "has continued to provide a refund service to parents in accordance with its terms and conditions" and is continuing to process refunds.It also said the terms and conditions regarding refunds "have not changed"."The company planned and has been carrying out an orderly exit leaving time for schools to find alternative providers while continuing to support services for schools and parents until we have completed the exit," the statement said."We understand why some schools and parents are upset that we are making any charges, even though these charges are clearly stated in our terms and conditions."It remains our intention to complete our exit from the market responsibly and with the least impact on all concerned."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mirror
17 minutes ago
- Daily Mirror
Huge number of Brits face holiday chaos as travel firm loses license
A UK-based travel firm has lost a key license, leaving huge numbers of customers facing cancelled holidays this summer. Great Little Escapes, based in Sandhurst in Berkshire, used to specialise in "adventure holidays to relaxing spa holidays, beach holidays to city breaks, adults-only to fun-filled family resorts". However, it has now ceased as an ATOL holder. The company is different from and not connected in any way to Great Little Breaks. A notice from the Civil Aviation Authority said: 'The company based in Sandhurst, Berkshire traded under the names Your Holidays, Great Little Escapes, Tunisia First and websites and 'We are currently collating information from the company and will update this page as soon as possible. While waiting for further information, please do not submit a claim as these will be rejected. 'If you are a travel agent of Great Little Escapes LLP and you are currently holding consumer payments which you have not yet paid to Great Little Escapes LLP, you must not use these funds to refund consumers until you have received instructions from the Air Travel Trust. 'Travel agents will be individually contacted by the CAA with specific instructions for these bookings.' The news came in the month after a separate British travel firm went bust. Jetline Travel, a London-based company established in 2000 and parent company of Jetline Cruise, ceased trading as an ATOL holder in March. Now it has been taken into administration, according to TTG. It reported that Alan Clark, of financial recovery specialist Carter Clark, and Neil Bennett, of restructuring and insolvency firm Leonard Curtis, were appointed on 28 March. Administration occurs when a business can no longer meet its debt obligations, leading to a licensed insolvency practitioner to be appointed to either restructure the business and come to an arrangement with creditors, or to sell off assets, pay off creditors and liquidate the business. Jetline Travel took hundreds of thousands of people on holidays over its 25 years trading. In that quarter of a century the firm also traded under several other names including Bargain Late Holidays, Best Priced Holidays, Cruise and More, Elegant Getaways, Our Best Holidays and Save on Sun. The Mirror has attempted to contact Great Little Escapes for comment.
Reuters
17 minutes ago
- Reuters
Focus: US pharma bets big on China to snap up potential blockbuster drugs
June 16 (Reuters) - U.S. drugmakers are licensing molecules from China for potential new medicines at an accelerating pace, according to new data, betting they can turn upfront payments of as little as $80 million into multibillion-dollar treatments. Through June, U.S. drugmakers have signed 14 deals potentially worth $18.3 billion to license drugs from China-based companies. That compares with just two such deals in the year-earlier period, according to data from GlobalData provided exclusively to Reuters. That increased pace is expected to continue as U.S. drugmakers look to rebuild pipelines of future products to replace $200 billion worth of medicines that will lose patent protection by the end of the decade, analysts, investors, a banker and a drug company executive told Reuters. "They are finding very high-quality assets coming out of China and at prices that are much more affordable relative to perhaps the equivalent type of product that they might find in the United States," said Mizuho analyst Graig Suvannavejh. The total cost of licensing agreements, including low upfront payments and subsequent larger payouts, averaged $84.8 billion in the U.S., compared with $31.3 billion in China over the past five years, according to GlobalData. A licensing agreement grants a company the rights to develop, manufacture, and commercialize another company's pharmaceutical products or technologies in exchange for future target-based, or "milestone", payments while mitigating development risks. China's share of global drug development is now nearly 30%, while the U.S. share of the world's research and development has slipped 1% to about 48%, according to pharmaceutical data provider Citeline's report in March. Chinese companies have licensed experimental drugs to U.S. drugmakers that could be used for obesity, heart disease and cancer, reflecting abundant Chinese government investment in pharmaceutical and biotech research and development. While small molecules, like oral drugs, have been the most commonly licensed, there has been a notable shift toward novel treatments such as targeted cancer therapies and first-in-class medicines, Jefferies analysts said in a note in May. "Chinese biotechs are moving up the value chain by the day. They are... challenging their Western peers," said Macquarie Capital analyst Tony Ren. The growth is happening even as the U.S. and China have wrangled over tariffs and U.S. President Donald Trump pushes a made in America agenda. That has cut into traditional mergers and acquisitions, which are down 20%, with only 50 such transactions so far this year, according to data from database. Roughly a third of the assets that large pharmaceutical companies licensed in 2024 were from China, said Brian Gleason, head of biotech investment banking at Raymond James, who estimated such licensing deals would increase to between 40% and 50%. "I think it's only accelerating," Gleason said. The Trump administration is currently doing a national security investigation as it weighs if it will impose tariffs on the pharmaceutical sector. But one healthcare analyst said licensing deals should continue because the yet to be marketed products are not impacted by tariffs. "The law that gives the president the right to impose tariffs applies to goods. It explicitly excludes intellectual property," said Tim Opler, managing director in Stifel's global healthcare group. In May, Pfizer (PFE.N), opens new tab spent $1.25 billion upfront for the right to license an experimental cancer drug from China's 3SBio ( opens new tab. That is the largest such deal this year and could be worth up to $6 billion in payments to 3SBio if the drug is successful. Regeneron Pharmaceuticals (REGN.O), opens new tab in June paid $80 million upfront in a potential $2 billion deal for an experimental obesity drug from China's Hansoh Pharmaceuticals ( opens new tab. By licensing a drug in development, U.S. and European drugmakers get very quick access to a molecule which would take them longer and cost more to discover or design themselves, analysts say. U.S.-based drug developer Nuvation Bio (NUVB.N), opens new tab bought AnHeart Therapeutics in 2024, gaining access to the China-based company's experimental cancer drug taletrectinib, which received U.S. approval last week. "We consider our presence in China not only a great avenue for R&D, but we also view it as an inside track on obtaining further assets to grow our company further and find new and better therapies to offer patients," Nuvation CEO David Hung told Reuters. What makes China attractive, said EY analyst Arda Ural, "a fraction of the cost and then multiples of time." Analysts have pointed to large drugmakers strategically securing rights to drugs at lower cost and running efficient early-stage trials in China to obtain important data, paving the way for global trials and potential earlier market entry. "It's a little bit of a wakeup call to our industry," said Chen Yu, Managing Partner at U.S.-based healthcare investment firm TCGX.
Reuters
22 minutes ago
- Reuters
What are bitcoin treasury strategies, the latest trend in the public markets?
June 16 (Reuters) - Certain public companies, including one founded by President Donald Trump, have been going on a cryptocurrency buying spree, capitalizing on higher token prices and a softening regulatory environment to load up on the attention-grabbing investment. Sixty-one publicly-listed companies not primarily engaged in digital assets have adopted what are known as bitcoin treasury strategies, in which firms allocate a portion of their cash and reserves toward the world's largest cryptocurrency, according to a report from Standard Chartered. Here is what you need to know about the trend: Many of those companies are seeking to replicate the success of Strategy (MSTR.O), opens new tab, formerly known as MicroStrategy, a software company that began accumulating bitcoin in 2020 and now holds more than $63 billion worth. Its stock is up more than 3,000% since 2020 as the price of bitcoin has skyrocketed, hitting fresh all-time highs above $110,000 this year. Strategy copycats have doubled their holdings in bitcoin in just the last two months to collectively hold just under 100,000 bitcoin, Standard Chartered said. Those firms include Trump Media & Technology Group (DJT.O), opens new tab, which raised $2.5 billion last month to invest in bitcoin. While investors can readily buy bitcoin directly or through an exchange-traded fund, investors typically cannot get the same kind of leverage a public company might be able to get through the convertible debt markets to buy bitcoin. Companies like Strategy trade at a premium to their bitcoin holdings because investors believe that those firms can utilize their access to credit markets to purchase even more bitcoin. Strategy and Trump Media & Technology Group did not immediately respond to requests for comment. Besides Strategy and Trump Media & Technology Group, a joint venture announced in April between SoftBank, stablecoin issuer Tether, and Cantor Fitzgerald - previously helmed by U.S. Commerce Secretary Howard Lutnick - caught investors' attention. The group is launching a $3.6-billion venture called Twenty One with the goal of acquiring bitcoin. SolarBank, a Toronto-based solar energy company, announced this month it would implement a bitcoin treasury strategy, saying it would expose the company "to a new category of tech-savvy investors." SolarBank has not disclosed how much bitcoin it plans to buy, only saying that the allocation strategy will be determined by management. "Traditionally, people invest in utilities as (an) afterthought. It's a very low return. It's a stable return," said SolarBank CEO Richard Lu. "So, how do we bridge the excitement of the new world and a classic industry? We feel that the crypto part of that is a bridge we need to cross." Upexi (UPXI.O), opens new tab, a consumer products company, recently launched a treasury for Solana, another top cryptocurrency. "It is a great way for a company to really bring attention to itself and grow," said Brian Rudick, the firm's chief strategy officer. "If a company has a fiduciary duty to do what's best for shareholders, and if you're going to raise funds and invest it in the operating business, or if you can invest in funds and put it into a digital asset treasury that the market is rewarding companies that do so, you should do the latter," Rudick said. The trend comes as Trump has sought to overhaul U.S. cryptocurrency policy after courting cash from the industry on the campaign trail. He signed an executive order in March to establish a strategic bitcoin reserve and has hosted industry leaders at the White House. Those moves have boosted the price of bitcoin and other cryptocurrencies. "It may be that some firms are trying to get political attention. This is clearly something President Trump has signaled his interest in," said Chester Spatt, a finance professor at Carnegie Mellon University. The stark shift in policy under Trump "is a serious tailwind for more and more institutions to get into the space," said Roshan Robert, CEO of crypto exchange OKX. "How institutions are looking at building out treasury applications is just a part of that broader picture." It is unclear if the various crypto treasury strategies will ultimately be successful, particularly if firms are buying in now as prices flirt with record highs in a sector that is no stranger to volatility. Charles Schwab, in a report last month, noted that if a company has significant crypto holdings that suddenly collapse in value, the firm could experience a liquidity crisis. Standard Chartered estimated that if bitcoin were to fall back below $90,000 it would put half of companies' bitcoin treasuries underwater. "As always, there will be some really, really big winners and some really big losers whenever there's a mania like this," said Ravi Doshi, the global co-head of markets at crypto platform FalconX.
